Cci-779 (DrugBank: -)
2 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
13 | Multiple sclerosis/Neuromyelitis optica | 2 |
46 | Malignant rheumatoid arthritis | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2005-000171-18-FI (EUCTR) | 12/05/2005 | 18/04/2005 | A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3066A2-210-WW - N/A | A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3066A2-210-WW - N/A | Multiple Sclerosis (Relapsing-remitting MS and Secondary progressive MS with relapses) | Product Name: Temsirolimus Tablets Product Code: CCI-779 INN or Proposed INN: Temsirolimus Other descriptive name: WAY-130799 | Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development | NULL | Not Recruiting | Female: yes Male: yes | 180 | Finland | |||
2 | NCT00228397 (ClinicalTrials.gov) | November 2003 | 16/9/2005 | Study Evaluating CCI-779 in Relapsing Multiple Sclerosis | A Multicenter, Randomized, Double-blind, Long-term Extension Study to Determine the Safety, Tolerability, and Preliminary Efficacy of CCI-779 in Subjects With Relapsing Multiple Sclerosis. | Multiple Sclerosis, Relapsing-Remitting | Drug: CCI-779 | Wyeth is now a wholly owned subsidiary of Pfizer | NULL | Completed | N/A | N/A | Both | 221 | Phase 2 | NULL |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00076206 (ClinicalTrials.gov) | December 2003 | 15/1/2004 | Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy | A Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Efficacy and Safety of 3 Different Oral Dose Levels (1, 2, And 4 Mg) of CCI-779 in Subjects With Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy | Rheumatoid Arthritis | Drug: CCI-779;Drug: Placebo | Wyeth is now a wholly owned subsidiary of Pfizer | NULL | Terminated | 18 Years | 75 Years | Both | Phase 2 | United States |